Please assess the completion status of the following clinical trial:

Trial Title: Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient will undergo PCI for diagnostic and/or therapeutic purposes with a procedure that uses anticoagulation before the instrumentation and reversal of anticoagulation immediately after the procedure.~2. Male or female patients of any race, aged 18-80 years old.~3. The patient will be anti-coagulated with unfractionated heparin.~4. The patient is medically stable and physically and mentally able to participate in this study.~5. The patient has given written informed consent to participate in this study after fully understanding the implications and constraints of the protocol.~Exclusion Criteria:~1. The patient requires emergency surgery under conditions which prevent compliance with this protocol or which might cause unacceptable risk to the patient.~2. The patient requires any concomitant surgical procedures (e.g., carotid artery, CABG) during the PCI.~3. The patient has received any investigational drug within 30 days of study enrollment, or has had any prior exposure to PMX-60056.~4. The patient has any condition or abnormality which may, in the opinion of the Investigator, compromise the safety of the patient.~5. The patient is pregnant or breast feeding.~6. The patient is of childbearing potential and not under adequate contraceptive protection.~7. The patient has a history of clinically significant hematologic disease including heparin-induced thrombocytopenia, bleeding disorders, or platelet count \<100,000.~8. Severe impaired hepatic function (SGOT, SGPT \>2 x ULN).~9. History of AIDS, ± HIV.~10. History of allergy to heparin (beef or pig), protamine, or salmon.~11. History of chronic alcohol or drug abuse within the last one year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Heparin and PMX-60056 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).